Division of Urology, Department of Surgery, Tripler Army Medical Center, Honolulu, Hawaii.
J Urol. 2019 Oct;202(4):806-810. doi: 10.1097/JU.0000000000000304. Epub 2019 Sep 6.
The AUA (American Urological Association) Position Statement on opioid use recommends using opioids only when necessary. We sought to determine if routine prescribing of opioids is necessary for pain control after vasectomy, and if an association exists with persistent use.
We retrospectively reviewed the charts of patients who underwent vasectomy in clinic between April 2017 and March 2018. Patients were stratified into 2 groups, including those initially prescribed opioids and those not receiving opioid prescriptions at the time of vasectomy. The initial pain medication regimen depended on the standard prescription practice of each provider. Encounters with a medical provider for scrotal pain within 30 days, subsequent opioid prescriptions and new persistent opioid prescriptions between 90 and 180 days were compared between the 2 groups using the Fisher exact test.
Between April 2017 and March 2018 a total of 228 patients underwent clinic vasectomy as performed by 8 urologists. At the time of vasectomy 102 patients received opioid prescriptions and 126 received no opioid prescriptions. There was no statistically significant difference between the opioid and nonopioid groups in encounters for scrotal pain (12.7% vs 18.4%, p = 0.279). The incidence of new persistent opioid use was 7.8% in the opioid cohort compared to 1.5% in the nonopioid cohort (p = 0.046).
Opioids, which do not appear to be necessary in men who undergo vasectomy, were associated with persistent use in 7.8% of patients at 3 to 6 months. In the face of an opioid epidemic urologists should take action to limit over prescription of opioids after vasectomy.
美国泌尿外科学会(AUA)的阿片类药物使用立场声明建议仅在必要时使用阿片类药物。我们试图确定在输精管结扎术后控制疼痛是否需要常规开具阿片类药物,以及是否存在持续使用的关联。
我们回顾性地审查了 2017 年 4 月至 2018 年 3 月在诊所接受输精管结扎术的患者的病历。患者分为两组,一组最初开具阿片类药物,另一组在输精管结扎术时未开具阿片类药物处方。初始疼痛药物治疗方案取决于每位提供者的标准处方实践。使用 Fisher 精确检验比较两组在 30 天内因阴囊疼痛就诊、90 至 180 天内随后开具阿片类药物处方和新的持续阿片类药物处方的情况。
2017 年 4 月至 2018 年 3 月期间,共有 228 名患者接受了 8 名泌尿科医生进行的诊所输精管结扎术。在输精管结扎术时,102 名患者开具了阿片类药物处方,126 名患者未开具阿片类药物处方。在阴囊疼痛就诊方面,阿片类药物组和非阿片类药物组之间没有统计学显著差异(12.7%比 18.4%,p=0.279)。阿片类药物组新持续使用阿片类药物的发生率为 7.8%,而非阿片类药物组为 1.5%(p=0.046)。
在接受输精管结扎术的男性中,阿片类药物似乎不是必需的,但在 3 至 6 个月时与 7.8%的患者持续使用相关。在阿片类药物流行的情况下,泌尿科医生应采取行动限制输精管结扎术后阿片类药物的过度处方。